30 closest matches · ranked by relevance
Non-Small Cell Lung Cancer
Primary: Percentage of Participants With Objective Response According to Modified Response Evaluation Criteria in Solid Tumors (RECIST) — 32; 21; 23 percentage of participants
Anticancer Treatment
Primary: Progression Free Survival (PFS) by Investigator Assessment — 10.1; 4.4 Months — p=<0.001
Squamous NSCLC
Primary: PFS(Progression Free Survival) — 5.5; 4.9 months
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 8.5 months
Non-small Cell Lung Cancer (NSCLC)
Primary: Progression Free Survival (PFS) — 4.8; 2.6 month
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
Primary: Median Progression Free Survival (PFS) (Months) — 18.9; 10.2; 17.8; 9.8 Months — p=<0.0001
Non-Small Cell Lung Cancer
Primary: Overall Survival (OS) — 10.3; 9.2 Months — p=0.025
Non-small Cell Lung Cancer
Primary: Progression Free Survival (PFS) at 18-month — 65.5; 66.3 Percentage of participants
Non Small Cell Lung Cancer
Primary: Efficacy of Atezolizumab in Combination With Bevacizumab - PFS — 11.3 Months
Non-Small-Cell Lung Carcinoma · Liver Cancer · Adrenal Cancer
Primary: Progression-free Survival — 11.2 months
Non Small Cell Lung Cancer
Primary: Overall Survival — 26.81; 24.97 months — p=0.831
Lung Cancer
Primary: Objective Response Rate (ORR), Presented in Numbers of Participants — 0; 0; 1; 1 Participants
Carcinoma, Non-Small-Cell Lung
Primary: Disease Control Rate (DCR) After 12 Weeks Induction — 0.742 proportion of participants
Pulmonary Diseases · Neoplasms, Lung
Primary: Confirmed Objective Response (OR) Based Upon Modified Response Evaluation Criteria in Solid Tumors (RECIST) Assessed by the Independent Review Committee (IRC). — 0; 0…
Non-small Cell Lung Cancer · Efficacy
Primary: Progression Free Survival (PFS) — 168; 140 day
Non-Small Cell Lung Cancer
Primary: Overall Response Rate (ORR), the Percentage of Patients Who Experience an Objective Benefit From Treatment — 29; 50 percentage of participants
Metastatic Non-Small Cell Lung Cancer
Primary: Progression-free Survival (PFS) Among Subjects With KRAS Mutation Positive NSCLC (ITT Population) Treated With Erlotinib Plus Tivantinib Compared to Single Agent…
Non-Small Cell Lung Cancer
Primary: Percentage of Participants With Dose Limiting Toxicities (DLTs) — 0; 0 Percentage of participants
Non-Small Cell Lung Cancer
Primary: Percentage of Participants With Progression-free Survival at Week 52 — 22.5 Percentage of participants
Carcinoma, Non-Small-Cell Lung
Primary: The Primary Goal of This Study is to Show That the Addition of Bevacizumab to Cisplatin-based Chemotherapy in the Neoadjuvant Setting for Non-squamous Cell Carcinomas…
Non-Small Cell Lung Cancer
Primary: Overall Objective Response Rate (ORR) — 8.1; 10.9 percentage of participants
Cancer
Primary: Evaluation of Overall Survival — 50.4 weeks
Metastatic Non-squamous Non Small Cell Lung Cancer
Primary: The Primary Efficacy Endpoint is Progression Free Survival, Analyzed in the Treated Population. PFS is Assessed From Randomization Until Either Tumor Progression, as Per…
Lung Neoplasms · Carcinoma, Non-small Cell Lung
Primary: Percentage of Participants With Objective Response (OR) — 9.4 Percentage of participants
Oligometastatic Lung Adenocarcinoma
Primary: Feasibility as Measured by at Least Five Patients Will Need to Complete Local Therapy.
Non-small Cell Lung Cancer
Primary: Proportion of Subjects Surviving at One Year — 0.405 proportion
Non-Small Cell Lung Cancer
Primary: Progression-free Survival (PFS) — 3.1; 1.9 months
Non-small Cell Lung Cancer
Primary: Local Failure Free Survival — 9.4; 9.9 months
Non - Small Cell Lung Cancer NSCLC
Primary: Overall Survival (OS) — 11.7; 6.8; 11.5; 8.7 months — p=0.109
Non Small Cell Lung Cancer
Primary: 1 Year Progression Free Survival — 53.7 percentage of participants — p=0.0645